Dan Grau, MPhil

Advisor

Dan Grau is an Advisor at Raven and a Board Director at Avilar Therapeutics. An experienced biotech entrepreneur and operating executive, Dan previously served as seed-stage CEO at Avilar, CEO and co-founder at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). Dan is also an Advisor at HotSpot Therapeutics and previously served as a Board Director at TetraGenetics (acquired 2021), a Board Director at Research Alliance Corporation I, a member of the Concert Pharmaceuticals PAB, and an Advisor to Nimbus. Earlier in his career, he worked as a management consultant to large pharma companies, including Pharmacia and Eisai, focused on corporate and R&D strategy, M&A, and new product commercialization. Dan earned his BA with High Honors from Davidson College and his MPhil, MA, and MAR degrees from Yale University.